Journal of Nuclear Cardiology - Cardiac amyloidosis: Topical Collection
Cardiac amyloidosis is a form of restrictive infiltrative cardiomyopathy that confers significant mortality. Due to the relative rarity of cardiac amyloidosis, clinical and diagnostic expertise in the recognition and evaluation of individuals with suspected amyloidosis is mostly limited to a few expert centers.
This collection of recent JNC publications aims to present a comprehensive overview of the many different facets related to diagnosis and treatment.
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging (this opens in a new tab). Dorbala S, Ando Y, Bokhari S, et al.
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization (this opens in a new tab). Dorbala S, Ando Y, Bokhari S, et al.
Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR) (this opens in a new tab). Pilebro B, Arvidsson S, Lindqvist P, et al.
Standardization of (99m)Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis (this opens in a new tab). Bokhari S, Morgenstern R, Weinberg R, et al.
(18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis (this opens in a new tab). Morgenstern R, Yeh R, Castano A, et al.
Imaging cardiac innervation in amyloidosis (this opens in a new tab). Slart RHJA, Glaudemans AWJM, Hazenberg BPC, Noordzij W.
Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes (this opens in a new tab). Vranian MN, Sperry BW, Hanna M, et al.
State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis (this opens in a new tab). Singh V, Falk R, Di Carli MF, et al.
Apical sparing pattern of left ventricular myocardial Tc-99m-HMDP uptake in patients with transthyretin cardiac amyloidosis (this opens in a new tab). Van Der Gucht A, Cottereau A-S, Abulizi M, et al.
Setting the stage for the next step in cardiac amyloidosis imaging: Serial quantitative studies to assess disease activity (this opens in a new tab). Soman P & Masri A.
Excerpts and images reprinted from Dorbala S, Ando Y, Bokhari S, et al. (2019) ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging. J Nucl Cardiol. https://doi.org/10.1007/s12350-019-01760-6 (this opens in a new tab).
Figure 2 caption: Characteristic appearance of cardiac amyloidosis on echocardiography. (a)-(d) 2D echocardiography. (a) (parasternal long axis) and (b) (parasternal short axis) demonstrate increased LV wall thickness with a sparkling texture of the myocardium (yellow arrows) in a patient with primary (AL) cardiac amyloidosis. Also, note the small pericardial effusion (white arrows), which is often seen in patients with cardiac amyloidosis. (c) (apical 4-chamber view) demonstrates increased biventricular wall thickness, biatrial enlargement, and increased thickening of the interatrial septum (yellow arrow) and mitral valve leaflets (white arrow) in a patient with wild-type transthyretin cardiac amyloidosis. (d) Tissue Doppler imaging (TDI) tracing taken at the septal mitral annulus in a patient with ATTR cardiac amyloidosis. The TDI tracings shows the “5-5-5” sign (s’ [systolic], e’ [early diastolic], and a’ [late (atrial) diastolic] tissue velocities are all < 5 cm/s), which is seen in patients with more advanced cardiac amyloidosis. The dotted lines denote the 5 cm/s cut-off for systolic and diastolic tissue velocities. In addition to the decreased tissue velocities, isovolumic contraction and relaxation times (IVCT and IVRT, respectively) are increased and ejection time (ET) is decreased, findings also seen in patients with cardiac amyloidosis especially as the disease becomes more advanced